Summit Therapeutics
SMMT
11 hedge funds and large institutions have $21.9M invested in Summit Therapeutics in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more capital invested
Capital invested by funds: $18.3M → $21.9M (+$3.65M)
10% more funds holding
Funds holding: 10 → 11 (+1)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$46.4K |
| 2 |
Axa
Paris,
France
|
+$44.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$13.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$376K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$30.9K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$11.5K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$8.95K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LPU
1
Lansdowne Partners (UK)
London,
United Kingdom
| $7.52M | – | – | – |
|
|
2
Point72 Asset Management
Stamford,
Connecticut
| $7.49M | -$30.9K | -3,800 | -0.4% |
|
|
3
Axa
Paris,
France
| $2.99M | +$44.8K | +5,500 | +1% |
|
|
SFM
4
Sphera Funds Management
Tel Aviv,
Israel
| $1.56M | -$11.5K | -1,413 | -0.7% |
|
5
First Eagle Investment Management
New York
| $1.38M | – | – | – |
|
|
GPCM
6
Granite Point Capital Management
Boston,
Massachusetts
| $891K | +$917K | +112,676 | New |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $44K | +$46.4K | +5,700 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $13K | +$13.6K | +1,675 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $12K | +$2.23K | +274 | +23% |
|
|
10
Wells Fargo
San Francisco,
California
| $11K | -$8.95K | -1,100 | -44% |
|
|
LTFS
11
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
EAM
12
EverPoint Asset Management
Stamford,
Connecticut
| – | -$376K | -55,111 | Closed |
|
SMMT Hedge Fund Activity: Q2 2016 in Review
11 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2016, worth a combined $21.9M — up 20% from $18.3M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SMMT positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $46.4K. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $376K sold.
- 11 institutional investors held Summit Therapeutics (SMMT) as of Q2 2016, up from 10 in Q1 2016.
- Funds reported $21.9M of Summit Therapeutics stock for Q2 2016, up 20% quarter-over-quarter.
- 3 funds opened new Summit Therapeutics positions in Q2 2016 and 2 closed out, a net change of +1 holder.
- The largest Summit Therapeutics buyer in Q2 2016 was Deutsche Bank, an estimated $46.4K added.
- The largest Summit Therapeutics seller in Q2 2016 was EverPoint Asset Management, an estimated $376K sold.
Based on aggregated 13F filings for Q2 2016.